SubHero Banner

Sirturo® (bedaquiline) – Expanded indication

May 27, 2020 - The FDA approved Janssen’s Sirturo (bedaquiline), as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Sirturo should be reserved for use when an effective treatment regimen cannot otherwise be provided.

Download PDF